---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002027"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T20:59:12.530256+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech appoints Peter Weiler as CFO effective May 1, 2025, replacing Stephen Lemieux

## Summary
- Stephen Lemieux resigns as CFO effective May 1, 2025, to pursue other opportunities; will continue as a senior financial advisor under a consulting agreement.
- Peter J. Weiler appointed CFO effective May 1, 2025; base salary of $300,000 USD per annum, target annual bonus of 40% of base salary, and $2,000/month auto allowance.
- Weiler previously served as President of Exzell Pharma, Inc., and held business development roles at Biosyent Inc. and Cipher Pharmaceuticals Inc.
- If terminated without cause, Weiler receives 12-24 months base salary plus benefits; enhanced change-of-control severance of 24 months base salary.
- Lemieux's departure not due to any disagreement with Edesa; transition is planned and orderly.

## SEC filing metadata
- accession: 0001171843-25-002027
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/0001171843-25-002027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/f8k_040325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002027
- JSON: https://secwatch.observer/filing/0001171843-25-002027.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002027.txt

## Key facts
- Executive change
  Peter J. Weiler was appointed as Chief Financial Officer at Edesa Biotech, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/0001171843-25-002027-index.htm
- Executive change
  Stephen Lemieux resigned as Chief Financial Officer at Edesa Biotech, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/0001171843-25-002027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.